Clinical trials: Brief Psychotic Disorder
Schizophrenia
Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia
To determine the safety \& efficacy of brexpiprazole monotherapy in the treatment of adolescents with schizophrenia.
- Trial name
- NCT03198078
- Testing
- Brexpiprazole (OPC-34712), Aripiprazole
- Where
- United States
- Volunteers
- 316 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Mental Disorder, Family
SAFIR Family Talk - Investigating the Effect of The Family Talk Intervention
The goal of this clinical trial is to test the effect of the Family Talk Preventive Intervention compared to service as usual for families where a parent has mental illness.
- Conditions
- Mental Disorder, Family, Child, Parenting
- Trial name
- NCT05615324
- Testing
- Family Talk Preventive Intervention
- Where
- Denmark
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Parent-Child Relations, Parenting
Examine the Feasibility and Acceptability of Project Support
In this study, the investigators will conduct a proof-of-concept pilot trial of delivering the Project Support Positive Parenting Module (Project Support) to n = 30 families waiting for trauma-focused services.
- Conditions
- Parent-Child Relations, Parenting, Child Mental Disorder
- Trial name
- NCT06391229
- Testing
- Project Support
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Medical University of South Carolina
Schizophrenia
A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia
The objective of this study is to investigate the efficacy and safety of three different doses of aripiprazole (2 mg/day, 6-12 mg/day, 24-30 mg/day) orally administered over a period of 6 weeks in pediatric patients (aged 13-17…
- Trial name
- NCT01942161
- Testing
- Aripiprazole Low (2 mg/day), Aripiprazole Mid (6 - 12 mg/day), Aripiprazole High (24 - 30 mg/day)
- Where
- 8 sites in Japan
- Volunteers
- 106 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia
The objective of this study is to investigate the safety and efficacy of aripiprazole (initial dose 2 mg/day, maintenance dose 6-24 mg/day, maximum dose 30 mg/day) orally administered over a period of 52 weeks in subjects who…
- Trial name
- NCT01942148
- Testing
- Aripiprazole
- Where
- 8 sites in Japan
- Volunteers
- 68 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Delusional Disorder, Brief Psychotic Disorder
FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosis
FEEL-GOOD is a prospective multi-site single-blinded randomized controlled trial in young inpatients with acute early psychosis. Participants are randomized 1:1 to FEEL-GOOD plus treatment as usual (TAU) or TAU alone.
- Conditions
- Delusional Disorder, Brief Psychotic Disorder, Schizophreniform Disorder, Schizophrenia / Schizoaffective Disorder
- Trial name
- FEEL-GOOD (NCT07645443)
- Testing
- FEEL GOOD, Treatment as Usual (TAU)
- Where
- 8 sites in Germany
- Volunteers
- 252 people
- Sponsor
- Stephanie Mehl
Mental Disorder, COVID
Psychotherapy Strategies for the Treatment of Professionals and Students From Essential Services With High Levels of Emotional Distress in the Context of COVID-19
The study consists in a pragmatic superiority randomized controlled trial comparing different strategies of psychotherapy for professionals and students from essential services with high levels of emotional distress during the…
- Conditions
- Mental Disorder, COVID, Emotional Distress, Depression
- Trial name
- NCT04635618
- Testing
- Cognitive Behavioral Brief-Telepsychotherapy, Brief Interpersonal Telepsychotherapy, Telepsychoeducation
- Where
- Brazil
- Volunteers
- 999 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Paranoia
Acceptability and Feasibility of a Brief Paranoia Intervention.
The goal of this feasibility and acceptability trial is to test whether a new brief talking therapy can be successfully provided to and is suitable for adolescents (16-18) who are seeking help from Child and Adolescent Mental…
- Trial name
- TRUST (NCT07350954)
- Testing
- TRUST
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Lucy Jonas
Suicide, Suicide, Attempted
Suicide Prevention Among Recipients of Care
Randomized controlled trial to determine the best brief suicide prevention intervention for adults and adolescents who screen positive for suicidal ideation or behavior in emergency departments or primary care clinics.
- Conditions
- Suicide, Suicide, Attempted, Suicidal Ideation, Social Support
- Trial name
- SPARC (NCT04893447)
- Testing
- SPI+, SP+CC (Caring Contacts)
- Where
- United States
- Volunteers
- 1,520 people
- Sponsor
- St. Luke's Health System, Boise, Idaho
Schizophrenia, Schizoaffective Disorder
An Integrated Program for the Treatment of First Episode of Psychosis
The purpose of this study is to determine how services should be provided to reduce symptoms and improve life functioning for adolescents and adults who have been recently diagnosed with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Brief Psychotic Disorder
- Trial name
- RAISE ETP (NCT01321177)
- Testing
- Integrated Treatment, Community Care
- Where
- 33 sites in United States
- Volunteers
- 404 people
- Sponsor
- Northwell Health
Psychotic Disorders
Using Short Message Service as a Means of Clinical Engagement in Early Psychosis
Engagement with clinical services for youth with early psychosis represents a significant challenge, with up to 40% of patients dropping out of treatment in the first year.
- Trial name
- NCT04379349
- Testing
- SMS text messaging - interactive check-in, SMS text messaging - inactive control
- Where
- Canada
- Volunteers
- 61 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Schizophreniform Disorders
Benefits of Combining MCT With CR in the Recovery of Patients With Psychotic Spectrum Disorders
The goal of this clinical trial is to compare the efficacy of combined REHACOP + MCT alone in persons with nonaffective psychotic disorder in terms of recovery.
- Conditions
- Schizophrenia, Schizophreniform Disorders, Delusional Disorder, Brief Psychotic Disorder
- Trial name
- CR+MCTp (NCT06423651)
- Testing
- Cognitive Remediation (REHACOP), Metacognitive Training (MCT)
- Where
- Spain
- Volunteers
- 160 people
- Sponsor
- Universitat Autonoma de Barcelona
Psychosis, Substance Use
Brief Motivational Enhancement Therapy for Concurrent Disorders
The investigators are proposing a project that will examine the effectiveness of brief motivational enhancement therapy in a population with concurrent psychotic disorders and substance use disorders.
- Trial name
- NCT01924039
- Testing
- Brief Motivational Enhancement Therapy, treatment as usual
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- Centre for Addiction and Mental Health
Psychosis, Alcohol Use Disorder
Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis
Psychotic disorders impact 4.6 people per 1000 globally, with approximately 1.5 million Canadians affected. The age of onset for psychotic disorders often begin during the critical years of youth and early adulthood, resulting in…
- Conditions
- Psychosis, Alcohol Use Disorder, Cannabis Use Disorder
- Trial name
- NCT07056894
- Testing
- Action-Based Cognitive Remediation
- Where
- 2 sites in Canada
- Volunteers
- 50 people
- Sponsor
- Nova Scotia Health Authority